What is Eversight?
Founded in 1947, Eversight is a leading nonprofit eye bank dedicated to transforming lives by restoring sight and preventing blindness. The organization operates across Arizona, Connecticut, Illinois, Michigan, New Jersey, Ohio, and South Korea, serving as a comprehensive partner for eye and vision research. Eversight's extensive network is responsible for recovering, evaluating, and providing human eye tissue for transplantation, while also supporting critical research into blinding eye conditions. They actively promote donation awareness and provide humanitarian aid globally. The cutting-edge Eversight Center for Vision and Eye Banking Research in Cleveland facilitates scientific inquiry by supplying human eye tissue and biofluids, consulting on study design, and advancing eye banking and ophthalmology through internal research and development. Eversight's global initiatives are focused on eradicating corneal blindness by developing eye banks, providing clinical training, and supplying tissue for transplantation and research in underserved communities worldwide.
How much funding has Eversight raised?
Eversight has raised a total of $25.2M across 3 funding rounds:
Series A
$9.7M
Private Equity
$14.5M
Private Equity
$1M
Series A (2014): $9.7M with participation from Emergence Capital Partners
Private Equity (2016): $14.5M led by Sutter Hill Ventures and Emergence Capital Partners
Private Equity (2016): $999K, investors not publicly disclosed
Key Investors in Eversight
Emergence Capital Partners
Emergence Capital Partners is a venture capital firm focused on early-stage enterprise companies, aiming to be a valuable partner in transforming how the world works.
Sutter Hill Ventures
Sutter Hill Ventures is a leader in financing technology-based startups, leveraging extensive operating and venture capital experience to assist entrepreneurs in building market-leading companies.
What's next for Eversight?
The substantial enterprise-level investment underscores Eversight's critical role in addressing the global burden of vision loss, which affects one billion people, including 12 million suffering from corneal blindness. This capital infusion is expected to accelerate Eversight's global initiatives, further strengthening its capacity to build sustainable eye banking infrastructures in underserved regions, enhance clinical training programs for international eye surgeons and technicians, and expand the provision of corneal tissue for transplantation and research. The organization's commitment to innovation, as demonstrated by its research center, positions it to make significant advancements in ophthalmology and eye banking, ultimately driving progress towards the elimination of preventable blindness worldwide.
See full Eversight company page
